{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:30:04Z","timestamp":1792510204061,"version":"4.5.0"},"reference-count":11,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:sec id=\"ab-ybr230002-4\"><jats:title>Importance<\/jats:title><jats:p>The relative efficacy of ketamine and electroconvulsive therapy (ECT) in adults with major depressive episode (MDE) needs clarification.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ybr230002-5\"><jats:title>Objective<\/jats:title><jats:p>To compare depression rating outcomes with ketamine vs ECT in adults with MDE and to compare response and remission rates, number of sessions to response and remission, and adverse effects.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ybr230002-6\"><jats:title>Data Sources<\/jats:title><jats:p>Two investigators independently systematically searched MEDLINE, ScienceDirect, and Google Scholar databases using a combination of relevant Medical Subject Headings terms and free-text keywords from database inception through May 15, 2022, to identify relevant English-language trials.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ybr230002-7\"><jats:title>Study Selection<\/jats:title><jats:p>Parallel-group randomized clinical trials (RCTs).<\/jats:p><\/jats:sec><jats:sec id=\"ab-ybr230002-8\"><jats:title>Data Extraction and Synthesis<\/jats:title><jats:p>Two investigators independently extracted data and assessed risk of bias. One-week posttreatment outcomes were pooled as standardized mean difference (SMD; Hedges <jats:italic>g<\/jats:italic>) for continuous outcomes and risk ratio (RR) for categorical outcomes in random-effects meta-analyses.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ybr230002-9\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Efficacy outcomes were 1-week (or nearest) posttreatment depression ratings, 1-week (or nearest) study-defined response and remission rates, and number of sessions to treatment response and remission. Safety outcomes were reported adverse effects.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ybr230002-10\"><jats:title>Results<\/jats:title><jats:p>Five trials (ketamine group: n\u2009=\u2009141; ECT group: n\u2009=\u2009137) were meta-analyzed. The overall pooled SMD for posttreatment depression ratings was \u22120.39 (95% CI, \u22120.81 to 0.02; <jats:italic>I<jats:sup>2<\/jats:sup><\/jats:italic>\u2009=\u200945%; 5 RCTs). For this efficacy outcome, in a sensitivity analysis of methodologically stronger trials, ECT was superior to ketamine (SMD, \u22120.45; 95% CI, \u22120.75 to \u22120.14; <jats:italic>I<jats:sup>2<\/jats:sup><\/jats:italic>\u2009=\u20096%; 2 RCTs). ECT was also superior to ketamine for study-defined response (RR, 1.27; 95% CI, 1.06-1.53; <jats:italic>I<jats:sup>2<\/jats:sup><\/jats:italic>\u2009=\u20090%; 3 RCTs) and remission (RR, 1.43; 95% CI, 1.12-1.82; <jats:italic>I<jats:sup>2<\/jats:sup><\/jats:italic>\u2009=\u20090%; 2 RCTs) rates. No significant differences were noted between groups for number of sessions to response and remission and for cognitive outcomes. Key limitations were small number of studies, limited sample size, and high risk of bias in all trials.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ybr230002-11\"><jats:title>Conclusion and Relevance<\/jats:title><jats:p>The findings of this systematic review and meta-analysis suggest an efficacy advantage for ECT over ketamine in adults with MDE. These conclusions are tempered by the small number and size of existing trials.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2023.0562","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T15:02:32Z","timestamp":1681311752000},"page":"639","source":"Crossref","is-referenced-by-count":51,"title":["Ketamine vs Electroconvulsive Therapy for Major Depressive Episode"],"prefix":"10.1001","volume":"80","author":[{"given":"Vikas","family":"Menon","sequence":"first","affiliation":[{"name":"Department of Psychiatry, JIPMER, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natarajan","family":"Varadharajan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, ESIC Medical College and Hospital, KK Nagar, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Faheem","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, JIPMER, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chittaranjan","family":"Andrade","sequence":"additional","affiliation":[{"name":"Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental health and Neurosciences, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"ybr230002r1","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/jamapsychiatry.2022.3352","article-title":"Efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: a systematic review and meta-analysis.","volume":"79","author":"Rhee","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"7414","key":"ybr230002r2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ybr230002r3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","author":"Page","journal-title":"BMJ"},{"issue":"5","key":"ybr230002r4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/ijnp\/pyab088","article-title":"Racemic ketamine as an alternative to electroconvulsive therapy for unipolar depression: a randomized, open-label, non-inferiority trial (KetECT).","volume":"25","author":"Ekstrand","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"key":"ybr230002r5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jad.2020.07.066","article-title":"Antidepressant effects of ketamine and ECT: a pilot comparison.","volume":"276","author":"Sharma","year":"2020","journal-title":"J Affect Disord"},{"key":"ybr230002r6","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"ybr230002r7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4103\/abr.abr_166_18","article-title":"Comparative effect of intravenous ketamine and electroconvulsive therapy in major depression: a randomized controlled trial.","volume":"8","author":"Kheirabadi","year":"2019","journal-title":"Adv Biomed Res"},{"issue":"6","key":"ybr230002r8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/JCP.0000000000001289","article-title":"Comparison of rapid antidepressant and antisuicidal effects of intramuscular ketamine, oral ketamine, and electroconvulsive therapy in patients with major depressive disorder: a pilot study.","volume":"40","author":"Kheirabadi","year":"2020","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"ybr230002r9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.psychres.2013.12.008","article-title":"Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.","volume":"215","author":"Ghasemi","year":"2014","journal-title":"Psychiatry Res"},{"issue":"2","key":"ybr230002r10","doi-asserted-by":"publisher","first-page":"40348","DOI":"10.4088\/JCP.22f14451","article-title":"Important insights for the use of ketamine from randomized controlled trials that compared ketamine with electroconvulsive therapy in severe depression.","volume":"83","author":"Andrade","year":"2022","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"ybr230002r11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/bdi.v24.2","article-title":"Oral racemic ketamine for common clinical contexts in patients with major depressive disorder: an important intervention that treatment guidelines may never include.","volume":"24","author":"Andrade","year":"2022","journal-title":"Bipolar Disord"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2803758\/jamapsychiatry_menon_2023_br_230002_1685127825.56309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T15:11:54Z","timestamp":1686150714000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2803758"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.0562","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}